• SSGXXII
    Share

Trial Status

In Development

Cancer Type

GIST

If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.

Protocol Title

Three or five years of adjuvant imatinib for the treatment of patients with operable GIST with a high risk of relapse: A randomized phase III study.

PURPOSE OF THE STUDY

Three years of imatinib is considered the standard duration of post therapy for patients with operable high-risk GIST. Yet, many patients are still at a high risk of GIST recurrence after completion of three years of adjuvant imatinib, and might benefit from further adjuvant imatinib therapy. The aim of SSGXXII is to compare the effect of giving imatinib for 5 years against 3 years, in patients who have undergone surgery for GIST, with the intent to prevent the tumour from coming back. The trial will look at the effect of the efficacy and safety of 5 years of treatment compared to 3 years.

Contact Email

TBC

DETAILED INFORMATION AVAILABLE

More detailed information to come.

PRINCIPAL INVESTIGATOR

Professor John Zalcberg, Chair

A/Prof Sumitra Ananda, Co-Chair

Funding

TBC

Trial Status

In Development

Cancer Type

GIST

If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.